Sign in

CIK 0000730272

  • Large accelerated filer

REPLIGEN CORP

Sign in to watch
Ticker
RGEN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
042729386
Phone
+1 781-449-9560
Business address
41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
  1. 4 Option exercise Director acquired 19,000 shares (option exercise)
  2. 4 Planned sale Director sold 22,191 shares at an average $145.37 ($3,225,927)
  3. 4 Grant or award Chief Executive Officer acquired 17,631 shares (grant or award)
  4. 4 Returned to the company Director returned 13,146 shares (to the company)
  5. 4/A Insider Changes in Ownership
  6. 4 Open-market sale Senior VP, R&D sold 7,148 shares at an average $159.35 ($1,139,016)
  7. 4 Open-market sale Senior VP, R&D sold 4,465 shares at $165.67 ($739,717)
  8. 4 Option exercise Director acquired 5,000 shares (option exercise)
  9. 4 Open-market buy Director bought 1,615 shares at an average $124.94 ($201,776)
  10. 4 Open-market buy Director bought 1,200 shares at $125.45 ($150,540)
  11. 4 Open-market buy Chief Executive Officer bought 2,000 shares at $124.08 ($248,160)
  12. 4 Option exercise Director acquired 2,953 shares (option exercise)
  13. 4 Planned sale Chief Executive Officer sold 20,072 shares at an average $168.26 ($3,377,283)
  14. 4 Grant or award Director acquired 701 shares (grant or award)
  15. 4 Grant or award Director acquired 701 shares (grant or award)
  16. 4 Grant or award Director acquired 701 shares (grant or award)
  17. 4 Grant or award Director acquired 701 shares (grant or award)
  18. 4 Grant or award Director acquired 701 shares (grant or award)
  19. 4 Grant or award Director acquired 701 shares (grant or award)
  20. 4 Grant or award Director acquired 803 shares (grant or award)

Page 5 of 34 · 669 filings